Drug Research and Drug Development in the 21st Century
Science and Ethics
Herausgegeben:Philipp, Egon O.; Wolff, H. P.; Fleckenstein, A.
Drug Research and Drug Development in the 21st Century
Science and Ethics
Herausgegeben:Philipp, Egon O.; Wolff, H. P.; Fleckenstein, A.
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
Distinguished scientists and members of the medicalprofession discuss the research and development of safe andsuitable drugs for the long-term treatment of chronicdiseases. The book provides an up-to-date survey on newinsights and technologies - as well as ethicalconsiderations - , since traditional means and methods ofdrug research and drug development may no longer suffice tomeet the challenges of the next century.
Andere Kunden interessierten sich auch für
- Antiepileptic Drugs111,99 €
- Antimalarial Drug II116,99 €
- Clinical Pharmacology: Current Topics and Case Studies110,99 €
- Neurotrophic Factors74,99 €
- John GeigertThe Challenge of CMC Regulatory Compliance for Biopharmaceuticals158,99 €
- John GeigertThe Challenge of CMC Regulatory Compliance for Biopharmaceuticals117,99 €
- John GeigertThe Challenge of CMC Regulatory Compliance for Biopharmaceuticals154,99 €
-
-
-
Distinguished scientists and members of the medicalprofession discuss the research and development of safe andsuitable drugs for the long-term treatment of chronicdiseases. The book provides an up-to-date survey on newinsights and technologies - as well as ethicalconsiderations - , since traditional means and methods ofdrug research and drug development may no longer suffice tomeet the challenges of the next century.
Produktdetails
- Produktdetails
- Bayer AG Centenary Symposium
- Verlag: Springer / Springer Berlin Heidelberg / Springer, Berlin
- Artikelnr. des Verlages: 978-3-540-50961-5
- 1989.
- Seitenzahl: 324
- Erscheinungstermin: 3. Juli 1989
- Englisch
- Abmessung: 244mm x 170mm x 18mm
- Gewicht: 610g
- ISBN-13: 9783540509615
- ISBN-10: 3540509615
- Artikelnr.: 24936094
- Bayer AG Centenary Symposium
- Verlag: Springer / Springer Berlin Heidelberg / Springer, Berlin
- Artikelnr. des Verlages: 978-3-540-50961-5
- 1989.
- Seitenzahl: 324
- Erscheinungstermin: 3. Juli 1989
- Englisch
- Abmessung: 244mm x 170mm x 18mm
- Gewicht: 610g
- ISBN-13: 9783540509615
- ISBN-10: 3540509615
- Artikelnr.: 24936094
History and Philosophy of Bayer Pharmaceutical Research.- Science, Responsibility, and Society.- Opening Remarks.- Message of Greeting.- I. Unresolved Problems of Chronic Diseases.- Demographic and Epidemiologic Trends Today.- Atherosclerosis and Coronary Heart Disease.- Rheumatoid Arthritis: A Modell of Chronic Inflammation.- Alzheimer's Disease.- Obstructive Lung Disease.- Biological Approaches to Cancer Therapy.- Challenges and Obstacles hi Clinical Evaluations of Therapy.- Problems, Pitfalls, and Opportunities in Long-term Randomized Trials.- The Impact of Clinical Trials on Clinical Practice.- Panel Discussion I: Cost Effectiveness of Drug Development and Health Economics.- II. Advanced Technologies, Scientific Achievements.- Receptors and Messengers.- Low Density Lipoproteins and Hypercholesterolemia.- Leukotrienes in Airways and Blood Vessels.- Drug Design.- Opening Remarks.- Thoughts About Gene Regulation and Mammalian Development.- Protein Crystallography and Drug Design.- Applying Engineering Principles to the Design of Cellular Biology.- Analytical Pathophysiology and Biochemistry.- Opening Remarks.- Neurotransmitters in the Brain.- Mechanisms of Cancer Metastasis.- Panel Discussion II: Objectives of Basic Research and Predictive Value Preclinical Testing.- The Patient as a Subject to Medical Research.- Ethics of Drug Research and Drug Development.- The Functions of Ethical Committees.- Reduction of Risk to Patients Through Optimized Planning of Clinical Drug Development.- The Quality of Life of Hypertensive Patients in Long-term Studies.- Panel Discussion III: Who is Concerned with Patient Welfare in Research?.- Concluding Remarks.
History and Philosophy of Bayer Pharmaceutical Research.- Science, Responsibility, and Society.- Opening Remarks.- Message of Greeting.- I. Unresolved Problems of Chronic Diseases.- Demographic and Epidemiologic Trends Today.- Atherosclerosis and Coronary Heart Disease.- Rheumatoid Arthritis: A Modell of Chronic Inflammation.- Alzheimer's Disease.- Obstructive Lung Disease.- Biological Approaches to Cancer Therapy.- Challenges and Obstacles hi Clinical Evaluations of Therapy.- Problems, Pitfalls, and Opportunities in Long-term Randomized Trials.- The Impact of Clinical Trials on Clinical Practice.- Panel Discussion I: Cost Effectiveness of Drug Development and Health Economics.- II. Advanced Technologies, Scientific Achievements.- Receptors and Messengers.- Low Density Lipoproteins and Hypercholesterolemia.- Leukotrienes in Airways and Blood Vessels.- Drug Design.- Opening Remarks.- Thoughts About Gene Regulation and Mammalian Development.- Protein Crystallography and Drug Design.- Applying Engineering Principles to the Design of Cellular Biology.- Analytical Pathophysiology and Biochemistry.- Opening Remarks.- Neurotransmitters in the Brain.- Mechanisms of Cancer Metastasis.- Panel Discussion II: Objectives of Basic Research and Predictive Value Preclinical Testing.- The Patient as a Subject to Medical Research.- Ethics of Drug Research and Drug Development.- The Functions of Ethical Committees.- Reduction of Risk to Patients Through Optimized Planning of Clinical Drug Development.- The Quality of Life of Hypertensive Patients in Long-term Studies.- Panel Discussion III: Who is Concerned with Patient Welfare in Research?.- Concluding Remarks.